About Finch. Finch is a clinical-stage company developing novel microbiome drugs to serve patients with serious unmet medical needs. Our machine learning-based platform mines molecular data collected from human interventional studies to identify the microbial communities driving positive patient outcomes in different disease areas. By developing drugs from microbial communities that have already demonstrated therapeutic effects in humans, we are pioneering a new approach to drug discovery and rapidly transforming the promise of the microbiome into a reality for patients. Our lead therapeutic c... view job details
About Finch. Finch is a clinical-stage company developing novel microbiome drugs to serve patients with serious unmet medical needs. Our machine learning-based platform mines molecular data collected from human interventional studies to identify the microbial communities driving positive patient outcomes in different disease areas. By developing drugs from microbial communities that have already demonstrated therapeutic effects in humans, we are pioneering a new approach to drug discovery and rapidly transforming the promise of the microbiome into a reality for patients. Our lead therapeutic c... view job details
About Finch. Finch is a clinical-stage company developing novel microbiome drugs to serve patients with serious unmet medical needs. Our machine learning-based platform mines molecular data collected from human interventional studies to identify the microbial communities driving positive patient outcomes in different disease areas. By developing drugs from microbial communities that have already demonstrated therapeutic effects in humans, we are pioneering a new approach to drug discovery and rapidly transforming the promise of the microbiome into a reality for patients. Our lead therapeutic c... view job details
About Finch. Finch is unlocking the therapeutic potential of the microbiome via a human-first drug discovery platform. We support clinical studies that intentionally manipulate the microbiome to investigate causality in diseases that are otherwise poorly understood. Using high-throughput molecular data from clinical studies and ex-vivo experiments, we identify specific strains that drive clinical phenotypes and responses to microbial therapies. Our team values transparency, integrity, humility, and collaboration, and we intend to have fun while maximizing our ability to make an impact on patie... view job details
About Finch. Finch is unlocking the therapeutic potential of the microbiome via a human-first drug discovery platform. We support clinical studies that intentionally manipulate the microbiome to investigate causality in diseases that are otherwise poorly understood. Using high-throughput molecular data from clinical studies and ex-vivo experiments, we identify specific strains that drive clinical phenotypes and responses to microbial therapies. Our team values transparency, integrity, humility, and collaboration, and we intend to have fun while maximizing our ability to make an impact on patie... view job details
About Finch. Finch is unlocking the therapeutic potential of the microbiome via a human-first drug discovery platform. We support clinical studies that intentionally manipulate the microbiome to investigate causality in diseases that are otherwise poorly understood. Using high-throughput molecular data from clinical studies and ex-vivo experiments, we identify specific strains that drive clinical phenotypes and responses to microbial therapies. Our team values transparency, integrity, humility, and collaboration, and we intend to have fun while maximizing our ability to make an impact on patie... view job details
About Finch. Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its. Human-First Discovery. platform to develop a novel class of orally administered biological drugs.. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for recurrent. C. difficile. infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first... view job details
About Finch. Finch is unlocking the therapeutic potential of the microbiome via a human-first drug discovery platform. We support clinical studies that intentionally manipulate the microbiome to investigate causality in diseases that are otherwise poorly understood. Using high-throughput molecular data from clinical studies and ex-vivo experiments, we identify specific strains that drive clinical phenotypes and responses to microbial therapies. Our team values transparency, integrity, humility, and collaboration, and we intend to have fun while maximizing our ability to make an impact on patie... view job details
About Finch. Finch is a clinical-stage company developing novel microbiome drugs to serve patients with serious unmet medical needs. Our machine learning-based platform mines molecular data collected from human interventional studies to identify the microbial communities driving positive patient outcomes in different disease areas. By developing drugs from microbial communities that have already demonstrated therapeutic effects in humans, we are pioneering a new approach to drug discovery and rapidly transforming the promise of the microbiome into a reality for patients.. Our lead therapeutic ... view job details
About Finch. Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its. Human-First Discovery. platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for recurrent. C. difficile. infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first ... view job details